<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63976">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273050</url>
  </required_header>
  <id_info>
    <org_study_id>D1680C00009</org_study_id>
    <nct_id>NCT02273050</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the
      Efficacy and Safety of Saxagliptin in Combination with Metformin IR as Initial Therapy
      Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects with Type 2
      Diabetes who have Inadequate Glycaemic Control
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allocation: Randomized Endpoint Classification: Efficacy/Safety study Intervention Model:
      Parallel Assignment Masking: Double Blind Primary Purpose: Treatment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in HbA1c from baseline to week 24(prior to rescue)</measure>
    <time_frame>From baseline to week 24(prior to rescue)</time_frame>
    <description>The primary efficacy variable is the change in HbA1c from baseline to week 24 (prior to rescue)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving a glycaemic response(defined as HbA1c &lt;7.0%) at week 24(prior to rescue)</measure>
    <time_frame>From baseline to week 24(prior to rescue)</time_frame>
    <description>Proportion of subjects achieving Hb1Ac&lt;7.0% at Week 24 (prior to rescue)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in fasting plasma glucose (FPG) from baseline to Week 24 (prior to rescue)</measure>
    <time_frame>From baseline to week 24(prior to rescue)</time_frame>
    <description>Change from baseline to Week 24 (prior to rescue) in fasting plasma glucose (FPG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline to Week 24 (prior to rescue) in the Area Under Curve from 0 to 180 minutes for postprandial glucose (PPG) in response to a meal tolerance test in a subset of approximately 256 subjects</measure>
    <time_frame>From baseline to week 24 (prior to rescue)</time_frame>
    <description>Change from baseline to week 24 in the Area Under Curve from 0 to 180 minutes for PPG in response to a meal tolerance test (MTT) in a subset of approximately 256 subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving a therapeutic glycaemic response defined as HbA1c ≤6.5% at Week 24 (prior to rescue)</measure>
    <time_frame>From baseline to week 24(prior to rescue)</time_frame>
    <description>Proportion of subjects achieving Hb1Ac≤6.5% at Week 24 (prior to rescue)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline to Week 24 (prior to rescue) in 120-minute postprandial plasma glucose (PPG) in a subset of approximately 256 subjects</measure>
    <time_frame>From baseline to week 24(prior to rescue)</time_frame>
    <description>Change in 120 minutes PPG from baseline to week 24(prior to rescue) in a subset of approximately 256 subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects requiring rescue for failing to achieve pre-specified glycaemic targets or discontinuing for lack of efficacy within the 24 weeks, double-blind treatment phase</measure>
    <time_frame>From baseline to week 24 (prior to rescue)</time_frame>
    <description>Proportion of subjects requiring rescue within the 24 weeks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The incidence of AE and of marked abnormalities in clinical lab tests in all subjects</measure>
    <time_frame>From screening to week24</time_frame>
    <description>The incidence of adverse events and of marked abnormalities in clinical laboratory tests in all subjects throughout the study</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1136</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Saxagliptin 5 mg + Metformin (500 mg with titration)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saxagliptin 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin 5 mg + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saxagliptin 5 mg once daily and Placebo 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin (500 mg with titration) + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin 5 mg</intervention_name>
    <description>Tablet, Oral, 5 mg, Once daily in the morning</description>
    <arm_group_label>Saxagliptin 5 mg + Metformin (500 mg with titration)</arm_group_label>
    <arm_group_label>Saxagliptin 5 mg + Placebo</arm_group_label>
    <other_name>Onglyza</other_name>
    <other_name>BMS-477118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 5 mg for Saxagliptin</intervention_name>
    <description>Tablet, Oral, 5 mg, Once daily in the morning</description>
    <arm_group_label>Metformin (500 mg with titration) + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 500 mg for metformin (with titration)</intervention_name>
    <description>Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.</description>
    <arm_group_label>Saxagliptin 5 mg + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 500 mg with titration</intervention_name>
    <description>Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.</description>
    <arm_group_label>Saxagliptin 5 mg + Metformin (500 mg with titration)</arm_group_label>
    <arm_group_label>Metformin (500 mg with titration) + Placebo</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Subjects with type 2 diabetes mellitus; 2. HbA1c ≥8% but ≤12%; 3.Fasting C-peptide ≥1.0
        ng/ml; 4. Subject will be drug naïve; 5. Body mass index ≤40 kg/m2.

        Exclusion Criteria:

        1. Symptoms of poorly controlled diabetes; 2. Chronic or repeated intermittent
        corticosteroid treatment ; 3. Calculated creatinine clearance &lt;60 ml/min or serum
        creatinine &gt;132.6 μmol/L (&gt;1.5 mg/dL) for men, &gt;123.8 μmol/L (&gt;1.4 mg/dL) for women; 4.
        Creatine Kinase ≥3x ULN; 5.Abnormal TSH value at screening will be further evaluated by
        free T4, subjects with an abnormal free T4 will be excluded; 6. History of administration
        of any antihyperglycaemic therapy for a total of 28 days or for more than three
        consecutive days or a total of seven non-consecutive days during the eight weeks prior to
        screening; 7. Current treatment with a strong CYP3A4/5 inhibitor; 8. Prior treatment with
        saxagliptin or any DPP-4 inhibitor; 9. Significant or history of cardiovascular disease,
        renal disease, psychiatric disorders, Immunocompromised individuals, hemoglobinopathies,
        liver disease, Pancreatitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changyu Pan, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The General Hospital of People's liberation Army</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuangchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guiyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ha'er bin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siping</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuxi</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yueyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 24, 2016</lastchanged_date>
  <firstreceived_date>October 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus, Dipeptidyl-Peptidase 4 Inhibitors, Saxagliptin, Metformin, Endocrine System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
